Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective of this study is to evaluate whether genomic based risk-stratification can be used in deciding whether to de-intensify in patients with Human Papillomavirus (HPV)-associated Oropharyngeal Squamous Cell Carcinoma (OPSCC) with > 10 pack years smoking history. Hypothesis: Patients with HPV-associated OPSCC, > 10 pack years smoking history, and non-mutated p53 will have similar 2 year progression-free survival (PFS) as patients with < 10 pack years smoking history.
The proposed study is a follow-up study to LCCC 1120 and 1413. The investigators have shown that de-intensification is efficacious in these two phase II studies. A major question is whether the investigators can de-intensify in patients with HPV-associated oropharyngeal cancer who have smoking histories. The investigators' hypothesis is that genomic profiling of patients' tumors (specifically for p53 mutations) will help in triaging patients to de-intensification versus standard of care. Patients with HPV-associated OPSCC will be enrolled regardless of smoking history and p53 mutational status will be assessed in patients with a smoking history. The investigators will use the same de-intensification chemoradiotherapy regimen already evaluated in LCCC 1120 and 1413 in patients with HPV-associated OPSCC who have a minimal smoking history and in patients with a smoking history but with wild-type p53. Patients with a smoking history who have mutated p53 will not receive de-intensified chemoradiotherapy, but instead will receive standard doses. The hypothesis is that by using genomics in the patients with a significant smoking history, the investigators will better select those who can be safely de-intensified. Circulating free HPV DNA (cf-HPV-DNA) will also be prospectively assessed from blood samples.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Radiotherapy and/or chemotherapy. | Experimental | Subjects with Oropharyngeal Squamous Cell Carcinoma receiving radiotherapy and/or chemotherapy. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Intensity Modulated Radiotherapy (IMRT) | Radiation | 60- 70 Gy at 2 Gy/fx |
|
| Measure | Description | Time Frame |
|---|---|---|
| Progression Free Survival (PFS) | PFS was assessed as the time from the first day of chemoradiation therapy (CRT) until disease progression. Disease progression was defined as biopsy proven tumor cells. Positron emission tomography / computerized tomography (PET/CT) was performed at week 10-16 (optimally at week 12) after completion of therapy. Biopsies were performed for subjects with imaging or clinical exam results suspicious for tumor. Clinical follow-up occurred and chest imaging was performed during the follow-up. | Two years after completion of the treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Plasma Circulating Free DNA -Baseline | The number of subjects who have or do not have plasma circulating free Human papillomavirus Deoxyribonucleic acid (HPV- DNA) was tabulated. | Baseline |
| Number of Participants With Plasma Circulating Free DNA -3months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Wendell Gray Yarbrough, MD | University of North Carolina at Chapel Hill, Department of Radiation Oncology | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Florida | Gainesville | Florida | 32610 | United States | ||
| University of Florida Proton Therapy Institute |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 32017652 | Derived | Chera BS, Kumar S, Shen C, Amdur R, Dagan R, Green R, Goldman E, Weiss J, Grilley-Olson J, Patel S, Zanation A, Hackman T, Blumberg J, Patel S, Thorp B, Weissler M, Yarbrough W, Sheets N, Mendenhall W, Tan XM, Gupta GP. Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal Cancer. J Clin Oncol. 2020 Apr 1;38(10):1050-1058. doi: 10.1200/JCO.19.02444. Epub 2020 Feb 4. |
| Label | URL |
|---|---|
| University of North Carolina Lineberger Comprehensive Cancer Center Clinical Trials | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A total of 195 subjects consented and started the study. Research at two study sites terminated early. Each site collected and stored the research data for its participants in its own systems. The validity of existing, sequestered data from sites 3 and 4 cannot be confirmed and may not be reliable. Therefore, arm/group and follow-up data related to sixty-nine subjects are not included and 126 subjects with arm/group and follow-up were presented.
Participants were recruited from 08/25/2016 through 12/11/2020 at 4 cancer centers in the United States.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Group A | Subjects with oropharyngeal squamous cell carcinoma have more than 10 years of smoking history, without p53 mutation and receiving 60Gy radiotherapy with or without chemotherapy. |
| FG001 | Group B |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Aug 18, 2023 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Cisplatin (or alternative) | Drug | The acceptable weekly chemotherapy regimens are Cisplatin 30 to 40 mg/m2 (first choice), Cetuximab 250mg/m2 (second choice), Carboplatin AUC 1.5 and paclitaxel 45 mg/m2 (third choice), Carboplatin AUC 3 (fourth choice). Chemotherapy will be given intravenously weekly during IMRT, 6 -7 total doses. |
|
| Assessment for surgical evaluation | Procedure | Decision for surgical evaluation will be based on the results of the PET/CT and clinical exam 10-16 weeks after CRT. Patients with a positive PET/CT scan will undergo surgical evaluation at the discretion of the surgeon. Patients with a negative PET/CT scan will be observed. |
|
The number of subjects who have or do not have plasma circulating free Human papillomavirus Deoxyribonucleic acid (HPV- DNA) was tabulated. |
| 3 months after completion of the treatment |
| Number of Participants With Plasma Circulating Free DNA -1 Year | The number of subjects who have or do not have plasma circulating free Human papillomavirus Deoxyribonucleic acid (HPV- DNA) was tabulated. | 1 year after completion of the treatment |
| Number of Participants With Plasma Circulating Free DNA -2 Year | The number of subjects who have or do not have plasma circulating free Human papillomavirus Deoxyribonucleic acid (HPV- DNA) was tabulated. | 2 years after completion of the treatment |
| Local Control Rate | The local control rate is defined as the total disappearance of the primary tumor without any local recurrence. Local recurrence was defined as biopsy-proven tumor cells in the primary tumor region. Biopsy was performed for a subject with a positive positron emission tomography / computerized tomography scan and /or clinical discretion of the surgeon 16 weeks after completion of the treatment. | 2 years after completion of the treatment |
| Regional Control Rate | Regional control rate is defined as the total disease disappearance of the related lymph node metastases without any lymph node recurrence. Regional recurrence was defined as biopsy proven tumor cells in related lymph nodes. Biopsy was performed for a subject with a positive positron emission tomography / computerized tomography scan and /or clinical discretion of the surgeon 16 weeks after completion of the treatment. | 2 years post-CRT |
| Local-regional Control Rate | Local-regional control rate is defined as the total disappearance of the primary tumor and related lymph node metastases without any recurrence. Local-regional recurrence was defined as biopsy-proven tumor cells in the primary tumor region and/or related lymph nodes. Biopsy was performed for a subject with a positive positron emission tomography / computerized tomography scan and /or clinical discretion of the surgeon 16 weeks after completion of the treatment. | 2 years after completion of the treatment |
| Distant Metastasis Free Survival | Distant metastasis-free survival is defined as the time from the first day of the study treatment to the date of disease spreads while subjects are alive. Distant metastasis-free survival is defined as no disease outside of the primary tumor and related lymph node metastases. Distant metastasis was defined as biopsy-proven tumor cells outside of the primary tumor and related lymph node metastases. Biopsy was performed for a subject with a positive positron emission tomography / computerized tomography scan and /or clinical discretion of the surgeon 16 weeks after completion of the treatment. | Two years after completion of the treatment |
| Overall Survival Rate | The overall survival rate is defined as the time from the first day of the study treatment to the date of death for any cause. Subjects who have not had an event will be censored at the date of the last assessment documenting the subject was alive. | Up to 2 years after completion of treatment |
| Jacksonville |
| Florida |
| 32206 |
| United States |
| University of North Carolina at Chapel Hill, Department of Radiation Oncology | Chapel Hill | North Carolina | 27599 | United States |
| Rex Healthcare | Raleigh | North Carolina | 27607 | United States |
Subjects with oropharyngeal squamous cell carcinoma have equal to or less than 10 years of smoking history, without p53 mutation and receiving 60Gy radiotherapy with or without chemotherapy
| FG002 | Group C | Subjects with oropharyngeal squamous cell carcinoma have more than 10 years of smoking history and with the p53 mutation and/or treating physicians' discretion receiving 70Gy radiotherapy with or without chemotherapy. |
| FG003 | Group DataUnknown | Research at two study sites terminated early. Each site collected and stored the research data for its participants in its own systems. Demographic data and site assignment for all subjects were stored centrally. Therefore, arm/group and follow-up data related to sixty-nine subjects are missing. |
| Assessment and Biopsy Was Done if Required at 2 Years After Treatment |
|
| COMPLETED |
|
| NOT COMPLETED |
|
|
Research at two study sites terminated early. Each site collected and stored the research data for its participants in its own systems. The validity of existing, sequestered outcome data from sites 3 and 4 cannot be confirmed and may not be reliable. Therefore, arm/group data related to sixty-nine subjects are not included in the data tables.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Group A | Subjects with oropharyngeal squamous cell carcinoma have more than 10 years of smoking history, without p53 mutation and receiving 60Gy radiotherapy with or without chemotherapy. |
| BG001 | Group B | Subjects with oropharyngeal squamous cell carcinoma have equal to or less than 10 years of smoking history, without p53 mutation and receiving 60Gy radiotherapy with or without chemotherapy. |
| BG002 | Group C | Subjects with oropharyngeal squamous cell carcinoma have more than 10 years of smoking history and with the p53 mutation and/or treating physicians' discretion receiving 70Gy radiotherapy with or without chemotherapy. |
| BG003 | Group Data Unknown | Research at two study sites terminated early. Each site collected and stored the research data for its participants in its own systems. Demographic data and site assignment for all subjects were stored centrally. Therefore, arm/group and follow-up data related to sixty-nine subjects are missing. |
| BG004 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Progression Free Survival (PFS) | PFS was assessed as the time from the first day of chemoradiation therapy (CRT) until disease progression. Disease progression was defined as biopsy proven tumor cells. Positron emission tomography / computerized tomography (PET/CT) was performed at week 10-16 (optimally at week 12) after completion of therapy. Biopsies were performed for subjects with imaging or clinical exam results suspicious for tumor. Clinical follow-up occurred and chest imaging was performed during the follow-up. | Subjects completed the study procedures including treatment, PET/CT, and biopsy when required, and followed up 2 years after completion of the treatment. Research at two study sites terminated early. Each site collected and stored the research data for its participants in its own systems. The validity of existing, sequestered outcome data from sites 3 and 4 cannot be confirmed and may not be reliable. Therefore, arm/group and follow-up data related to sixty-nine subjects are not included. | Posted | Count of Participants | Participants | Two years after completion of the treatment |
|
|
| ||||||||||||||||||||||||||||||||||
| Secondary | Number of Participants With Plasma Circulating Free DNA -Baseline | The number of subjects who have or do not have plasma circulating free Human papillomavirus Deoxyribonucleic acid (HPV- DNA) was tabulated. | Subjects started the treatment and provided specimens for plasma circulating free HPV DNA analysis at baseline. Research at two study sites terminated early. Each site collected and stored the research data for its participants in its own systems. The validity of existing, sequestered outcome data from sites 3 and 4 cannot be confirmed and may not be reliable. Therefore, arm/group and follow-up data related to sixty-nine subjects are not included. | Posted | Count of Participants | Participants | Baseline |
| ||||||||||||||||||||||||||||||||||||
| Secondary | Number of Participants With Plasma Circulating Free DNA -3months | The number of subjects who have or do not have plasma circulating free Human papillomavirus Deoxyribonucleic acid (HPV- DNA) was tabulated. | Subjects completed the study treatment and provided specimens for plasma circulating free HPV DNA analysis at 3 months after the completion of radiotherapy. Research at two study sites terminated early. Each site collected and stored the research data for its participants in its own systems. The validity of existing, sequestered outcome data from sites 3 and 4 cannot be confirmed and may not be reliable. Therefore, arm/group and follow-up data related to sixty-nine subjects are not included. | Posted | Count of Participants | Participants | 3 months after completion of the treatment |
| ||||||||||||||||||||||||||||||||||||
| Secondary | Number of Participants With Plasma Circulating Free DNA -1 Year | The number of subjects who have or do not have plasma circulating free Human papillomavirus Deoxyribonucleic acid (HPV- DNA) was tabulated. | Subjects completed the study treatment and provided specimens for plasma circulating free HPV DNA analysis 1 year after the completion of radiotherapy. Research at two study sites terminated early. Each site collected and stored the research data for its participants in its own systems. The validity of existing, sequestered outcome data from sites 3 and 4 cannot be confirmed and may not be reliable. Therefore, arm/group and follow-up data related to sixty-nine subjects are not included. | Posted | Count of Participants | Participants | 1 year after completion of the treatment |
| ||||||||||||||||||||||||||||||||||||
| Secondary | Number of Participants With Plasma Circulating Free DNA -2 Year | The number of subjects who have or do not have plasma circulating free Human papillomavirus Deoxyribonucleic acid (HPV- DNA) was tabulated. | Subjects completed the study treatment and provided specimens for plasma circulating free HPV DNA analysis 2 years after the completion of radiotherapy. Research at two study sites terminated early. Each site collected and stored the research data for its participants in its own systems. The validity of existing, sequestered outcome data from sites 3 and 4 cannot be confirmed and may not be reliable. Therefore, arm/group and follow-up data related to sixty-nine subjects are not included. | Posted | Count of Participants | Participants | 2 years after completion of the treatment |
| ||||||||||||||||||||||||||||||||||||
| Secondary | Local Control Rate | The local control rate is defined as the total disappearance of the primary tumor without any local recurrence. Local recurrence was defined as biopsy-proven tumor cells in the primary tumor region. Biopsy was performed for a subject with a positive positron emission tomography / computerized tomography scan and /or clinical discretion of the surgeon 16 weeks after completion of the treatment. | Subjects completed the study procedures including treatment, PET/CT, and biopsy when required, and followed up 2 years after completion of the treatment. Research at two study sites terminated early. Each site collected and stored the research data for its participants in its own systems. The validity of existing, sequestered outcome data from sites 3 and 4 cannot be confirmed and may not be reliable. Therefore, arm/group and follow-up data related to sixty-nine subjects are not included. | Posted | Count of Participants | Participants | 2 years after completion of the treatment |
| ||||||||||||||||||||||||||||||||||||
| Secondary | Regional Control Rate | Regional control rate is defined as the total disease disappearance of the related lymph node metastases without any lymph node recurrence. Regional recurrence was defined as biopsy proven tumor cells in related lymph nodes. Biopsy was performed for a subject with a positive positron emission tomography / computerized tomography scan and /or clinical discretion of the surgeon 16 weeks after completion of the treatment. | Subjects completed the study procedures including treatment, PET/CT, and biopsy when required, and followed up 2 years after completion of the treatment. Research at two study sites terminated early. Each site collected and stored the research data for its participants in its own systems. The validity of existing, sequestered outcome data from sites 3 and 4 cannot be confirmed and may not be reliable. Therefore, arm/group and follow-up data related to sixty-nine subjects are not included. | Posted | Count of Participants | Participants | 2 years post-CRT |
| ||||||||||||||||||||||||||||||||||||
| Secondary | Local-regional Control Rate | Local-regional control rate is defined as the total disappearance of the primary tumor and related lymph node metastases without any recurrence. Local-regional recurrence was defined as biopsy-proven tumor cells in the primary tumor region and/or related lymph nodes. Biopsy was performed for a subject with a positive positron emission tomography / computerized tomography scan and /or clinical discretion of the surgeon 16 weeks after completion of the treatment. | Subjects completed the study procedures including treatment, PET/CT, and biopsy when required, and followed up 2 years after completion of the treatment. Research at two study sites terminated early. Each site collected and stored the research data for its participants in its own systems. The validity of existing, sequestered outcome data from sites 3 and 4 cannot be confirmed and may not be reliable. Therefore, arm/group and follow-up data related to sixty-nine subjects are not included. | Posted | Count of Participants | Participants | 2 years after completion of the treatment |
| ||||||||||||||||||||||||||||||||||||
| Secondary | Distant Metastasis Free Survival | Distant metastasis-free survival is defined as the time from the first day of the study treatment to the date of disease spreads while subjects are alive. Distant metastasis-free survival is defined as no disease outside of the primary tumor and related lymph node metastases. Distant metastasis was defined as biopsy-proven tumor cells outside of the primary tumor and related lymph node metastases. Biopsy was performed for a subject with a positive positron emission tomography / computerized tomography scan and /or clinical discretion of the surgeon 16 weeks after completion of the treatment. | Subjects completed the study procedures including treatment, PET/CT, and biopsy when required, and followed up 2 years after completion of the treatment. Research at two study sites terminated early. Each site collected and stored the research data for its participants in its own systems. The validity of existing, sequestered outcome data from sites 3 and 4 cannot be confirmed and may not be reliable. Therefore, arm/group and follow-up data related to sixty-nine subjects are not included. | Posted | Count of Participants | Participants | Two years after completion of the treatment |
| ||||||||||||||||||||||||||||||||||||
| Secondary | Overall Survival Rate | The overall survival rate is defined as the time from the first day of the study treatment to the date of death for any cause. Subjects who have not had an event will be censored at the date of the last assessment documenting the subject was alive. | Research at two study sites terminated early. Each site collected and stored the research data for its participants in its own systems. The validity of existing, sequestered outcome data from sites 3 and 4 cannot be confirmed and may not be reliable. Therefore, arm/group and follow-up data related to sixty-nine subjects are not included. | Posted | Count of Participants | Participants | Up to 2 years after completion of treatment |
|
2 years
The protocol does not require adverse event assessment. Adverse Event Data was not collected.
Research at two study sites terminated early. Each site collected and stored the research data for its participants in its own systems. The validity of existing, sequestered outcome data from sites 3 and 4 cannot be confirmed and may not be reliable. Therefore, arm/group and follow-up data related to sixty-nine subjects are not included.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Group A | Subjects with oropharyngeal squamous cell carcinoma have more than 10 years of smoking history, without p53 mutation and receiving 60Gy radiotherapy with or without chemotherapy. Research at two study sites terminated early (halted prematurely due to non-compliance in the performance of the study). Therefore, follow-up data is missing. Data from these subjects is not included in survival calculations. | 1 | 18 | 0 | 0 | 0 | 0 |
| EG001 | Group B | Subjects with oropharyngeal squamous cell carcinoma have equal to or less than 10 years of smoking history, without p53 mutation and receiving 60Gy radiotherapy with or without chemotherapy. Research at two study sites terminated early (halted prematurely due to non-compliance in the performance of the study). Therefore, follow-up data is missing. Data from these subjects is not included in survival calculations. | 4 | 105 | 0 | 0 | 0 | 0 |
| EG002 | Group C | Subjects with oropharyngeal squamous cell carcinoma have more than 10 years of smoking history and with the p53 mutation and/or treating physicians' discretion receiving 70Gy radiotherapy with or without chemotherapy. Research at two study sites terminated early (halted prematurely due to non-compliance in the performance of the study). Therefore, follow-up data is missing. Data from these subjects is not included in survival calculations. | 0 | 3 | 0 | 0 | 0 | 0 |
| EG003 | Group DataUnknown | Research at two study sites terminated early. Each site collected and stored the research data for its participants in its own systems. Demographic data and site assignment for all subjects were stored centrally. Therefore, arm/group and follow-up data related to sixty-nine subjects are missing. | 0 | 69 | 0 | 0 | 0 | 0 |
Not provided
Not provided
Research at two study sites terminated early. Each site collected and stored the research data for its participants in its own systems. The validity of existing, sequestered outcome data from sites 3 and 4 cannot be confirmed and may not be reliable. Therefore, arm/group and follow-up data related to sixty-nine subjects are not included in the data tables.
LCCC1612 is a multi-site study. Three of the four site investigators are not employees of the Sponsor. Restrictions to disclosure do not apply due to circumstances of non-compliance. Study data was sequestered, data is not accessible for further analysis or publication.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Melahat G. Canter MD MS Clinical Trial Analyst | University of North Carolina Lineberger Comprehensive Cancer Center | (919) 962-0000 | Melahat_Canter@med.unc.edu |
| Oct 20, 2023 |
| Prot_SAP_000.pdf |
| ID | Term |
|---|---|
| D002294 | Carcinoma, Squamous Cell |
| D006258 | Head and Neck Neoplasms |
| D009959 | Oropharyngeal Neoplasms |
| D000077195 | Squamous Cell Carcinoma of Head and Neck |
| ID | Term |
|---|---|
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D018307 | Neoplasms, Squamous Cell |
| D009371 | Neoplasms by Site |
| D010610 | Pharyngeal Neoplasms |
| D010039 | Otorhinolaryngologic Neoplasms |
| D010608 | Pharyngeal Diseases |
| D009057 | Stomatognathic Diseases |
| D010038 | Otorhinolaryngologic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D050397 | Radiotherapy, Intensity-Modulated |
| D002945 | Cisplatin |
| D012149 | Restraint, Physical |
| ID | Term |
|---|---|
| D020266 | Radiotherapy, Conformal |
| D011881 | Radiotherapy, Computer-Assisted |
| D011878 | Radiotherapy |
| D013812 | Therapeutics |
| D017606 | Chlorine Compounds |
| D007287 | Inorganic Chemicals |
| D017672 | Nitrogen Compounds |
| D017671 | Platinum Compounds |
| D032763 | Behavior Control |
| D007103 | Immobilization |
| D008919 | Investigative Techniques |
Not provided
Not provided
| Male |
|
| Not Hispanic or Latino |
|
| Unknown or Not Reported |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
|
|
|
Subjects with oropharyngeal squamous cell carcinoma have more than 10 years of smoking history and with the p53 mutation and/or treating physicians' discretion receiving 70Gy radiotherapy with or without chemotherapy.
|
|
Subjects with oropharyngeal squamous cell carcinoma have more than 10 years of smoking history and with the p53 mutation and/or treating physicians' discretion receiving 70Gy radiotherapy with or without chemotherapy.
|
|
Subjects with oropharyngeal squamous cell carcinoma have more than 10 years of smoking history and with the p53 mutation and/or treating physicians' discretion receiving 70Gy radiotherapy with or without chemotherapy.
|
|
| OG002 | Group C | Subjects with oropharyngeal squamous cell carcinoma have more than 10 years of smoking history and with the p53 mutation and/or treating physicians' discretion receiving 70Gy radiotherapy with or without chemotherapy. |
|
|
| OG002 | Group C | Subjects with oropharyngeal squamous cell carcinoma have more than 10 years of smoking history and with the p53 mutation and/or treating physicians' discretion receiving 70Gy radiotherapy with or without chemotherapy. |
|
|
| OG002 | Group C | Subjects with oropharyngeal squamous cell carcinoma have more than 10 years of smoking history and with the p53 mutation and/or treating physicians' discretion receiving 70Gy radiotherapy with or without chemotherapy. |
|
|
| OG002 | Group C | Subjects with oropharyngeal squamous cell carcinoma have more than 10 years of smoking history and with the p53 mutation and/or treating physicians' discretion receiving 70Gy radiotherapy with or without chemotherapy. |
|
|
|
|